Switching from intravenous tocilizumab to subcutaneous administration during COVID19 pandemic – impact on treatment efficacy and patient satisfaction

Back to Abstracts

Switching from intravenous tocilizumab to subcutaneous administration during COVID19 pandemic – impact on treatment efficacy and patient satisfaction

  • Rula Daood, Kochava Toledano, Doron Markovits, Yonit Tavor, Samy Giries, Katya Dolnikov, Helani Jiries, Alexandra Balbir-Gurman and Yolanda Braun-Moscovici
Previous E-Poster Download E-Poster Next E-Poster